^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MORF-088
i
Other names: MORF-088, MORF088, MORF 088
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Eli Lilly, Schrodinger
Drug class:
αVβ8 integrin inhibitor
Related drugs:
over3years
[VIRTUAL] Inhibition of integrin αvβ8 enhances immune checkpoint induced anti-tumor immunity by acting across immunologic synapse in syngeneic models of breast cancer (AACR 2021)
Efficacy was confirmed in PyMT breast cancer model.Conclusions An αvβ8 inhibitor in combination with anti-PD-1 showed efficacy in syngeneic mouse models, supported by increased T cell infiltrates and evidence of reduced tumor tolerance. These results show that an orally administered αvβ8 targeted inhibitor is a potent modulator of anti-tumor immune response acting across the immunologic synapse, and is a promising therapeutic approach to ICB refractory tumors.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD69 (CD69 Molecule) • IL10 (Interleukin 10) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL2 (Chemokine (C-C motif) ligand 2) • TGFB1 (Transforming Growth Factor Beta 1) • CCL22 (C-C Motif Chemokine Ligand 22) • CD40 (CD40 Molecule)
|
IFNG expression
|
MORF-088
Share via
